Analytical Data
-
Gene name
DPPIV/CD26
- Application
-
Alternative Names
CD26; ADA; DPPIV; DPP-IV; DPP4; ADABP; ADCP2; TP103; Adenosine Deaminase Complexing Protein 2; T-cell activation antigen CD26; Dipeptidyl Peptidase IV
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P27487
-
Expression Region
Ser484~Val728
-
Molecular Weight
29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Dipeptidyl peptidase IV (DPPIV), also known as CD26, is a serine protease enzyme that plays a crucial role in various physiological and pathological processes, including immune regulation, cell adhesion, and glucose metabolism. Its ability to cleave N-terminal dipeptides from proteins, particularly those involved in the incretin pathway, positions DPPIV as a significant target for therapeutic interventions in metabolic disorders such as diabetes and obesity. Additionally, CD26 is implicated in the activation and migration of T cells, making it a potential marker for immune response and a target for immunotherapy in cancer. Research on recombinant DPPIV/CD26 proteins focuses on understanding their structure-function relationships, enzymatic activity, and interaction with ligands and inhibitors. By producing these proteins recombinantly, scientists aim to facilitate studies into their biological roles and potential applications, including the development of DPPIV inhibitors as novel antidiabetic agents. Furthermore, insights gained from recombinant DPPIV/CD26 can enhance the understanding of its involvement in various diseases, paving the way for innovative therapeutic strategies. Overall, the exploration of DPPIV/CD26 through recombinant protein research holds promising implications for both metabolic and immune-related conditions.
